Filter posts

Important Perspectives on Innovation and Costs

This is an exciting time in biomedical innovation. New and highly innovative therapies are coming …

ICYMI: Dr. Ted Love explains “why drug pricing controls could impede innovation”

Risky. Costly. Time consuming. Rewarding. Those few words help describe a biopharmaceutical ecosystem where 90% …

The Empty Promise of “Safe” Drug Importation

For years, BIO has been urging both state and federal policymakers to adopt responsible solutions …

Insurers Shift Costs and Facts

As health insurance companies begin setting rates for 2019, many consumers are once again faced …

On the President’s Drug Cost Plan, Three Important Concerns

Part 3. Restricting access under Medicaid Is not the answer This week, BIO launched a …

The Latest Good News on Prescription Drug Costs

Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These …

ICER Comes Under Renewed Scrutiny

As we enter a new and exciting era of medicine, there is an important question …

#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described …

Here We Go Again (But In a Good Way)

“We achieved the lowest drug trend since we began measuring drug trend data in 1993.” …

“A Transformative Year in Medicine”

2017 will be remembered as an exciting year for biopharmaceutical innovation. Not only did we …